Regentis Biomaterials closed a US $15MM Series D investment round. Funds will primarily support a pivotal U.S. clinical trial of GelrinC®, a cell-free implant for the treatment of articular knee cartilage injuries.
OsteoVantage was awarded a US $0.15MM SBIR Phase I grant. Funds will support enhancements to INDOS™, a spinal instrumentation system that employs electroactive pedicle screws to encourage posterolateral fusion.
CartiHeal completed a US $15MM financing round. Funds will support ongoing manufacturing scale-up, EU product commercialization in 2017 and clinical studies in new therapeutic areas for Agili-C™ cartilage regeneration technology.